Belvedere Trading Reduces $692K in Inhibrx Biosciences, Inc. ($INBX)
Key Points
- Belvedere Trading changed its Inhibrx Biosciences, Inc. ($INBX) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $INBX is Buy and an average price target of $277.50.
- $INBX last traded around $93.54.
Belvedere Trading reduced its position in Inhibrx Biosciences, Inc. ($INBX), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Inhibrx Biosciences, Inc. after selling 7,402 shares during the quarter.
Inhibrx Biosciences, Inc. ($INBX) Stock
Inhibrx Biosciences, Inc. Earnings
Analysts Set New Price Targets
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.